肝衰竭诊治指南（2018年版）

doi:10.3969/j.issn.1672-5069.2019.02.004

Abstract

Guideline for diagnosis, treatment of liver failure. [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 164-171.

[1] Polson J,Lee WM.AASLD position paper:the management of acute liver failure[J]. Hepatology,2005,41(5):1179-1197. DOI: 10.1002/hep.20703.
[2] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊疗指南[J]. 中华肝脏病杂志,2006,14(9):643-646. Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,Chinese Medical Association;Severe Liver Diseases and Artificial Liver Group,Chinese Society of Hepatology,Chinese Medical Association. Diagnostic and treatment guidelines for liver failure[J].Chin J Hepatol,2006,14(9):643-646. (in Chinese)
[3] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版)[J].中华临床感染病杂志,2012,5(6):321-327. DOI:10.3969/j.issn.1672-5069.2013.03.007. Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,CMA;Severe Liver Disease and Artificial Liver Group,Chinese Society of Hepatology,CMA. Guideline for diagnosis and treatment of liver failure[J]. Chin J Clin Infect Dis,2012,5(6):321-327. DOI10.3969/j.issn.1672-5069.2013.03.007.(in Chinese)
[4] Sarin SK,Kedarisetty CK,Abbas Z,et al.Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL) 2014[J]. Hepatol Int,2014,8(4):453-471. DOI: 10.1007/s12072-014-9580-2.
[5] European Association for the Study of the Liver. EASL clinical practical guidelines on the management of acute (fulminant) liver failure[J]. J Hepatol,2017,66(5):1047-1081. DOI: 10.1016/j.jhep.2016.12.003.
[6] Flamm SL,Yang YX,Singh S,et al.American gastroenterological association institute guidelines for the diagnosis and management of acute liver failure[J]. Gastroenterology,2017,152(3):644-647. DOI:10.1053/j.gastro.2016.12.026.
[7] Wu T,Li J,Shao L,et al.Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. Gut,2018,67(12):2181-2191. DOI:10.1136/
gutjnl-2017-314641.
[8] Jalan R,Yurdaydin C,Bajaj JS,et al.Toward an improved definition of acute-on-chronic liver failure[J]. Gastroenterology,2014,147(1):4-10. DOI:10.1053/j.gastro.2014.05.005.
[9] Zhang Q,Li Y,Han T,et al.Comparison of current diagnostic criteria for acute-on-chronic liver failure[J/OL]. PLoS One,2015,10(3):e0122158. DOI:10.1371/journal.pone.0122158.
[10] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease[J]. J Hepatol,2018,pii:S0168-8278(18):32177-32179. DOI:10.1016/
j.jhep.2018.06.024.
[11] Chen Y,Yang F,Lu H,et al.Characterization of fecal microbial communities in patients with liver cirrhosis[J]. Hepatology,2011,54(2):562-572. DOI:10.1002/hep.24423.
[12] Tilg H,Cani PD,Mayer EA.Gut microbiome and liver diseases[J]. Gut,2016,65(12):2035-2044. DOI:10.1136/gutjnl-2016-
312729.
[13] Petrof EO,Khoruts A. From stool transplants to next-generation microbiota therapeutics[J]. Gastroenterology,2014,146(6):1573-
1582. DOI: 10.1053/j.gastro.2014.01.004.
[14] Rockey DC,Seeff LB,Rochon J,et al.Causality assessment in drug-induced liver injury using a structured expert opinion process:comparison to the Roussel-Uclaf causality assessment method[J]. Hepatology,2010,51(6):2117-2126. DOI: 10.1002/
hep.23577.
[15] Jindal A,Kumar M,Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B[J]. Liver Int,2013,33 Suppl 1:164-175. DOI:10.1111/liv.12081.
[16] Sun LJ,Yu JW,Zhao YH,et al.Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure[J]. J Gastroenterol Hepatol,2010,25(3):583-590. DOI:10.1111/j.1440-1746.2009.06089.x.
[17] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol,2018,69(2):461-511. DOI:10.1016/j.jhep.2018.03.026.
[18] Smilkstein MJ,Knapp GL,Kulig KW,et al.Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985)[J]. N Engl J Med,1988,319(24):1557-1562. DOI: 10.1056/NEJM198812153192401.
[19] Keays R,Harrison PM,Wendon JA,et al.Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure:a prospective controlled trial[J]. BMJ,1991,303(6809):1026-1029. DOI:10.1136/bmj.303.6809.1026.
[20] Lee WM,Hynan LS,Rossaro L,et al.Intravenous N-acetylcysteine improves transplant-free survival in early stage non-
acetaminophen acute liver failure[J]. Gastroenterology,2009,137(3):856-864. DOI:10.1053/j.gastro.2009.06.006.
[21] Hruby K,Csomos G,Fuhrmann M,et al.Chemotherapy of amanita phalloides poisoning with intravenous silibinin[J]. Hum Toxicol,1983,2(2):183-195.
[22] Broussard CN,Aggarwal A,Lacey SR,et al.Mushroom poisoning-from diarrhea to liver transplantation[J]. Am J Gastroenterol,2001,96(11):3195-3198. DOI:10.1111/j.1572-0241.2001.05283.x.
[23] Enjalbert F,Rapior S,Nouguier-Soulé J,et al.Treatment of amatoxin poisoning:20-year retrospective analysis[J]. J Toxicol Clin Toxicol,2002,40(6):715-757. DOI:10.1081/CLT-120014646.
[24] Canalese J,Gimson AE,Davis C,et al.Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure[J]. Gut,1982,23(7):625-629. DOI:10.1136/gut.23.7.625.
[25] Klinck J,McNeill L,Di Angelantonio E,et al. Predictors and outcome impact of perioperative serum sodium changes in a high-risk population[J]. Br J Anaesth,2015,114(4):615-622. DOI:10.1093/bja/aeu409.
[26] Jalan R,Olde Damink SW,Deutz NE,et al.Restoration of cerebral blood flow autoregulation and reactivity to carbon dioxide in acute liver failure by moderate hypothermia[J]. Hepatology,2001,34(1):50-54. DOI:10.1053/jhep.2001.25386.
[27] Jalan R,O Damink SW,Deutz NE,et al. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure[J]. Lancet,1999,354(9185):1164-1168. DOI:10.1016/S0140
-6736(98)12440-6.
[28] Tofteng F,Larsen FS.The effect of indomethacin on intracranial pressure,cerebral perfusion and extracellular lactate and glutamate concentrations in patients with fulminant hepatic failure[J]. J Cereb Blood Flow Metab,2004, 24(7):798-804. DOI10.1097/01.WCB.0000125648.03213.1D.
[29] 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南[J]. 中华内科杂志,2018,57(10):705-718. DOI:10.3760/cma.j.issn.0578-1426.
2018.10.004.Chinese Society of Hepatology,Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. Chin J Intern Med,2018,57(10):705-718. DOI:10.3760/cma.j.issn.0578-1426.2018.10.004.(in Chinese)
[30] Vilstrup H,Amodio P,Bajaj J,et al.Hepatic encephalopathy in chronic liver disease:2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver[J]. Hepatology,2014,60(2):715-735. DOI:10.1002/hep.27210.
[31] Gluud LL,Vilstrup H,Morgan MY.Nonabsorbable disaccharides for hepatic encephalopathy:A systematic review and meta-analysis[J]. Hepatology,2016,64(3):908-922. DOI: 10.1002/hep.28598.
[32] Gluud LL,Vilstrup H,Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis[J]. Cochrane Database Syst Rev,2016(5):p. CD003044. DOI:10.1002/14651858.CD003044.pub4.
[33] Bai M,Yang Z,Qi X,et al.L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis:a meta-analysis of randomized controlled trials[J]. J Gastroenterol Hepatol,2013,28(5):783-792. DOI:10.1111/jgh.12142.
[34] Gluud LL,Dam G,Les I,et al. Branched-chain amino acids for people with hepatic encephalopathy[J]. Cochrane Database Syst Rev,2017,5:CD001939. DOI:10.1002/14651858.CD001939.pub4.
[35] Laccetti M,Manes G,Uomo G,et al.Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients:a double blind randomized placebo controlled study[J]. Dig Liver Dis,2000,32(4):335-338.
[36] Hanish SI,Stein DM,Scalea JR,et al.Molecular adsorbent recirculating system effectively replaces hepatic function in severe acute liver failure[J]. Ann Surg,2017,266(4):677-684. DOI: 10.1097/SLA.0000000000002361.
[37] Saliba F,Camus C,Durand F,et al.Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized,controlled trial[J]. Ann Intern Med,2013,159(8):522-531. DOI: 10.7326/0003-4819-159-8-2013
10150-00005.
[38] Rolando N,Philpott-Howard J,Williams R.Bacterial and fungal infection in acute liver failure[J]. Semin Liver Dis,1996,16(4):389-402. DOI:10.1055/s-2007-1007252.
[39] Silvestre JP,Coelho LM,Póvoa PM.Impact of fulminant hepatic failure in C-reactive protein[J]. J Crit Care,2010,25(4):657. e7-12. DOI:10.1016/j.jcrc.2010.02.004.
[40] Rule JA,Hynan LS,Attar N,et al.Procalcitonin identifies cell injury,not bacterial infection,in acute liver failure[J/OL]. PLoS One,2015,10(9):e0138566. DOI:10.1371/journal.pone.0138566.
[41] Karvellas CJ,Cavazos J,Battenhouse H,et al. Effects of antimicrobial prophylaxis and blood stream infections in patients with acute liver failure:a retrospective cohort study[J]. Clin Gastroenterol Hepatol,2014,12(11):1942-1949. e1. DOI:10.1016/j.cgh.2014.03.011.
[42] Bernal W,Auzinger G,Dhawan A,et al.Acute liver failure[J]. Lancet,2010,376(9736):190-201. DOI:10.1016/S0140-6736(10)60274-7.
[43] Farmakiotis D,Kontoyiannis DP.Emerging issues with diagnosis and management of fungal infections in solid organ transplant recipients[J]. Am J Transplant,2015,15(5):1141-1147. DOI: 10.1111/ajt.13186.
[44] Uojima H,Kinbara T,Hidaka H,et al.Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites[J]. Hepatol Res,2017,47(3):E14-E21. DOI:10.1111/hepr.12716.
[45] Yan L,Xie F,Lu J,et al.The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites:a meta-analysis of randomized controlled trials[J]. BMC Gastroenterol,2015,15:65. DOI:10.1186/s12876-015-0297-z.
[46] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol,2018,69(2):406-460. DOI: 10.1016/j.jhep.2018.03.024.
[47] Mindikoglu AL,Pappas SC. New developments in hepatorenal syndrome[J]. Clin Gastroenterol Hepatol,2018,16(2):162-177. e1. DOI:10.1016/j.cgh.2017.05.041.
[48] Selby NM,Kubba AK,Hawkey CJ.Acid suppression in peptic ulcer haemorrhage:a 'meta-analysis'[J]. Aliment Pharmacol Ther,2000,14(9):1119-1126.
[49] Leontiadis GI,Sharma VK,Howden CW.Proton pump inhibitor therapy for peptic ulcer bleeding:Cochrane collaboration meta-analysis of randomized controlled trials[J]. Mayo Clin Proc,2007,82(3):286-296. DOI:10.4065/82.3.286.
[50] Ioannou G,Doust J,Rockey DC. Terlipressin for acute esophageal variceal hemorrhage[J]. Cochrane Database Syst Rev,2003,(1):CD002147. DOI:10.1002/14651858.CD002147.
[51] Imperiale TF,Teran JC,McCullough AJ. A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage[J]. Gastroenterology,1995,109(4):1289-1294.
[52] Laine L,Cook D.Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis[J]. Ann Intern Med,1995,123(4):280-287.
[53] Lin LL,Du SM,Fu Y,et al.Combination therapy versus pharmacotherapy,endoscopic variceal ligation,or the transjugular intrahepatic portosystemic shunt alone in the secondary prevention of esophageal variceal bleeding:a meta-analysis of randomized controlled trials[J]. Oncotarget,2017,8(34):57399-57408. DOI: 10.18632/oncotarget.18143.
[54] Pereira SP,Rowbotham D,Fitt S,et al.Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease[J]. J Hepatol,2005,42(3):365-370. DOI:10.1016/j.jhep.2004.11.030.
[55] 中华医学会感染病学分会肝衰竭与人工肝学组. 非生物型人工肝治疗肝衰竭指南(2016年版)[J]. 中华临床感染病杂志,2016,9(2):97-103. DOI:10.3760/cma.j.issn.1674-2397.2016.02.001. Liver Failure and Artificial Liver Group,Branch of Infectious Diseases,Chinese Medical Association. Guideline for non-bioartificial liver support systems in treatment of liver failure:2016 update[J]. Chin J Clin Infect Dis,2016,9(2):97-103. DOI10.3760/cma.j.issn.1674-2397.2016.02.001.(in Chinese)
[56] Steadman RH,Van Rensburg A,Kramer DJ.Transplantation for acute liver failure:perioperative management[J]. Curr Opin Organ Transplant,2010,15(3):368-373. DOI:10.1097/MOT.0b013e32
833982dd.
[57] Ling Q,Xu X,Wei Q,et al.Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure[J/OL]. PLoS One,2012,7(1):e30322. DOI: 10.1371/journal.pone.0030322.
[58] Mochida S. Indication criteria for liver transplantation for acute liver failure in Japan[J]. Hepatol Res,2008,38 Suppl 1:S52-55. DOI:10.1111/j.1872-034X.2008.00427.x.
[59] 饶慧瑛,郭芳,魏来. 2005年美国肝病学会急性肝衰竭诊治和肝移植患者评价指南简介[J].中华肝脏病杂志,2006,14(2):154-156. DOI:10.3760/j.issn:1007-3418.2006.02.025. Rao HY, Guo F,Wei L. Introduction and comments on AASLD practice guidelines:diagnosis and treatment of acute liver failure and assessment of liver transplant patients[J].Chin J Hepatol,2006,14(2):154-156. DOI10.3760/j.issn:1007-3418.2006.02.025. (in Chinese)
[60] Arroyo V,Moreau R,Kamath PS,et al.Acute-on-chronic liver failure in cirrhosis[J]. Nat Rev Dis Primers,2016,2:16041. DOI: 0.1038/nrdp.2016.41.
[61] Linecker M,Krones T,Berg T,et al. Potentially inappropriate liver transplantation in the era of the “sickest first” policy-A search for the upper limits[J]. J Hepatol,2017,pii:S0168-8278(17)32430-3. DOI:0.1016/j.jhep.2017.11.008.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[4]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[5]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[6]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[7]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[8]	. [J]. Journal of Practical Hepatology, 2019, 22(5): 624-635.
[9]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[10]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[11]	Song Haiyan, Chen Xi, Zhang Junfei, et al. Application of vorionazole in the treatment of patients with liver failure complicated by pulmonary fungal infection [J]. Journal of Practical Hepatology, 2019, 22(5): 676-679.
[12]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[13]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[14]	Zhang Xuan, Tang Xiaoyun, Tang Chunyin, et al. Effect of Chinese herbal medicine on intestinal microflora in mice with D-galactosamine/LPS-induced acute liver failure [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 478-481.
[15]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.